Actuate Therapeutics files S-1 for highly dilutive $41M public offering at $0.819/share amid delisting risk
ACTU sits 34% above its 52-week low of $0.604.
Summary
Actuate Therapeutics filed an S-1 to raise up to $47.1 million through a highly dilutive public offering of common stock at $0.819 per share, a move necessitated by its short cash runway and ongoing Nasdaq delisting risk. Konik Capital Partners is the underwriter, and Newbridge, a dealer, has conflicts including fees from Bios Fund III Entities and Series C placement.
Updated with an SEC FWP filing · What changed
Updates
· SEC FWP — Konik Capital Partners is the underwriter; Newbridge, a dealer, has conflicts including fees from Bios Fund III Entities and Series C placement.
Key Events · Financing and Capital Events · ACTU
-
New · · SEC FWP
Underwriter and Dealer Conflicts
Konik Capital Partners is the underwriter. Newbridge, a dealer, has conflicts including fees from Bios Fund III Entities and Series C placement.
-
Proposed Public Offering
The company is registering to sell 50,000,000 shares of common stock, with an over-allotment option for an additional 7,500,000 shares, at an assumed public offering price of $0.819 per share. This could raise up to $47.1 million before expenses.
-
Massive Dilution for Existing Shareholders
The offering represents a potential dilution of up to 239.4% to the 24,013,577 shares outstanding as of June 30, 2026, significantly impacting existing shareholder value.
-
Distressed Capital Raise
This offering follows a Nasdaq delisting notice in July 2026 and a Q2 2026 report indicating a cash runway only to September 2026, highlighting the company's urgent need for capital to continue operations.
-
Investor Warrants and Extended Lock-ups
Key investors (Bios and Kairos Entities), holding approximately 50% of outstanding shares, have agreed to a two-year lock-up period in exchange for warrants to purchase 3,700,000 shares at an exercise price of 150% of the offering price.
Analysis · ACTU · Life Sciences
Actuate Therapeutics has filed an S-1 registration statement for a public offering of 50,000,000 shares, with an option for underwriters to purchase an additional 7,500,000 shares, at an assumed price of $0.819 per share. This offering, if fully subscribed, could raise up to $47.1 million before expenses, but would result in massive dilution of up to 239.4% for existing shareholders, based on 24,013,577 shares outstanding as of June 30, 2026. This capital raise is critical for the company's survival, following a Nasdaq delisting notice in July 2026 and a Q2 2026 report indicating a cash runway only until September 2026. The offering price is significantly below prior financing rounds and the company's IPO price. Major investors (Bios and Kairos Entities), who collectively own approximately 50% of outstanding shares, have agreed to a two-year lock-up in exchange for warrants to purchase an aggregate of 3,700,000 shares at 150% of the offering price, indicating a sweetener for their long-term commitment during this distressed period. Konik Capital Partners is the underwriter, and Newbridge, a dealer, has conflicts including fees from Bios Fund III Entities and Series C placement.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 46.1% of the 282 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACTU was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.5M. The 52-week trading range was $0.60 to $8.49. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.